These innovative molecules represent a significant advancement in the therapy of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates promising efficacy in reducing blood glucose https://violabpss045026.win-blog.com/20135626/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide